"The Company also has greater China rights to ZEVALIN® (Ibritumomab Tiuxetan) and MARQIBO® (vincristine sulfate LIPOSOME injection), each of which is approved in the United States by the FDA for specified indications. Due to the evolving standard of care environment, the rare and niche indication for these products, and the Company’s commitment to prioritize resources, the Company is currently evaluating its options for these products."
Market Data 
Markets 
AI
